Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.31 |
| ▸ | RXRA | P19793 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633781 | 0.81 | ACHE (0.36) | ACHEHPGDPOLBCYP1A2HDAC1 | |
| SCHEMBL144695 | 0.81 | ACHE (0.36) | ACHEHPGDPOLBCYP1A2HDAC1 | |
| SCHEMBL172114 | 0.81 | ACHE (0.36) | ACHEDAO | |
| SCHEMBL67359 | 0.79 | ACHE (0.41) | ACHEHPGDCYP1A2RAPGEF4HDAC1 | |
| SCHEMBL31633778 | 0.79 | ACHE (0.41) | ACHEDAOPOLBCYP1A2RAPGEF4 | |
| SCHEMBL175646 | 0.79 | ACHE (0.41) | ACHEHPGDCYP1A2RAPGEF4HDAC1 | |
| SCHEMBL3475177 | 0.79 | ACHE (0.41) | ACHEDAOPOLBCYP1A2RAPGEF4 | |
| SCHEMBL384037 | 0.77 | ACHE (0.42) | ACHEDAORAPGEF4 | |
| SCHEMBL30064 | 0.77 | ACHE (0.42) | ACHEHPGDPOLBCYP1A2HDAC1 | |
| SCHEMBL8428973 | 0.77 | ACHE (0.39) | ACHEPOLBCYP1A2RAPGEF4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| EP-4310087-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| WO-2022087634-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS CLOTHO, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | ROLIC AG (CH) | 2008-11-06 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-1820504-A1 | IMINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007017752-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006119504-A2 | FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ACHE 230/4885HPGD 2124/4885DAO 856/4885 |
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | ACHE 1050/4885HPGD 1808/4885DAO 3379/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ACHE 3249/4885HPGD 2279/4885DAO 4682/4885 |
| US-20080274304-A1 | Functionalized Photoreactive Compounds | PCNA, PIN1, MAP1LC3C | ACHE 4372/4885HPGD 1529/4885DAO 2373/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ACHE 3249/4885HPGD 2279/4885DAO 4682/4885 |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | ACHE 1308/4885HPGD 10/4885DAO 1364/4885 |
| US-20230371357-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | L1CAM, CHRM1, FOXM1 | ACHE 574/4885HPGD 3849/4885DAO 2918/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ACHE 230/4885HPGD 2124/4885DAO 856/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | ACHE 1308/4885HPGD 10/4885DAO 1364/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | ACHE 230/4885HPGD 2124/4885DAO 856/4885 |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | ACHE 4868/4885HPGD 824/4885DAO 1884/4885 |
| US-20210371393-A1 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | ACHE 4001/4885HPGD 949/4885DAO 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.